Treating Type 1 diabetes: From strategies for insulin delivery to dual hormonal control

Minerva Endocrinologica

Volumn 38, Issue 2, 2013, Pages 145-163

  McCall, A L ^a   Farhy, L S ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Diabetes mellitus, type 1; Hans; Hyperglycemia; Hypoglycemia; Insulin; Islets of langer; Pancreas, artificial

Indexed keywords

GLUCOSE; INSULIN; INSULIN ASPART; INSULIN DEGLUDEC; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; INSULIN PEGLISPRO; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; PIG INSULIN; SHORT ACTING INSULIN;

AMINO ACID SUBSTITUTION; ARTICLE; ARTIFICIAL PANCREAS; BLOOD GLUCOSE MONITORING; DIABETIC PATIENT; DRUG DELIVERY SYSTEM; FOOD AND DRUG ADMINISTRATION; GLUCOSE BLOOD LEVEL; GLUCOSE SENSOR; GLYCEMIC CONTROL; HISTORY OF MEDICINE; HORMONAL REGULATION; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; IMPLANTABLE PUMP; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; INSULIN RELEASE; INSULIN TREATMENT;

BLOOD GLUCOSE SELF-MONITORING; DIABETES MELLITUS, TYPE 1; DRUG DELIVERY SYSTEMS; GLUCAGON; HISTORY, 20TH CENTURY; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN INFUSION SYSTEMS;

EID: 84882353232     PISSN: 03911977     EISSN: 18271634     Source Type: Journal    
DOI: None     Document Type: Article

References (73)

1. Bliss M. The Discovery of Insulin. Chicago, IL: University of Chicago Press; 1982.
2. Tibaldi JM. Evolution of insulin development: focus on key parameters. Adv Ther 2012;29:590-619.
3. Gualandi-Signorini AM, Giorgi G. Insulin formulations - a review. Eur Rev Med Pharmacol Sci 2001;5:73-83.
4. Dimitriadis G, Gerich J. Importance of timing of preprandial subcutaneous insulin administration in the management of diabetes mellitus. Diabetes Care 1983;6:374-7.
5. Little RR, Rohlfing CL. The long and winding road to optimal HbAlc measurement. Clin Chim Acta 2013;418 C: 63-71.
6. Higgins T. HbA (lc)-an analyte of increasing importance. Clin Biochem 2012;45:1038-45.
7. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993:329:977-86.
8. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28:103-17.
9. United Kingdom Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
10. McCall AL. Insulin therapy and hypoglycemia. Endocrinol Metab Clin North Am 2012;41:57-87.
11. Hirsch IB. Insulin analogues. N Engl J Med 2005;352:174-83.
12. Didangelos T, Iliadis F. Insulin pump therapy in adults. Diabetes Res Clin Pract 2011;93(Suppl 1):S109-13.
13. Shetty G, Wolpert H. Insulin pump use in adults with type 1 diabetes-practical issues. Diabetes Technol Ther 2010;12(Suppl 1):S11-6.
14. El-Khatib FH, Russell SJ, Nathan DM, Sutherlin RG, Damiano ER. A bihormonal closed-loop artificial pancreas for type 1 diabetes. Sci Transl Med 2010;2:27ra27.
15. Kowalski A, Lum JW. Juvenile Diabetes Research Foundation Artificial Pancreas Consortium Update. J Diab Sci Tech 2009;3:1224-6.
16. Haidar A, Legault L, Dallaire M, Alkhateeb A, Coriati A, Messier V et al. Glucose-responsive insulin and glucagon delivery (dual-hormone artificial pancreas) in adults with type 1 diabetes: a randomized crossover controlled trial. CMAJ 2013;185:297-305.
17. Bequette BW. Challenges and Recent Progress in the Development of a Closed-loop Artificial Pancreas. Annu Rev Control 2012;36:255-66.
18. Howey DC, Bowsher RR, Brunelle RL, Woodworth JR. [Lys (B28), Pro (B29)]-human insulin. A rapidly absorbed analogue of human insulin. Diabetes 1994;43:396-402.
19. Birkeland KI, Home PD, Wendisch U, Ratner RE, Johansen T, Endahl LA et al. Insulin degludec in type 1 diabetes: a randomized controlled trial of a newgeneration ultra-long-acting insulin compared with insulin glargine. Diabetes Care 2011;34:661-5.
20. Riddle, M. C, Rosenstock J, Gerich J. The treat-totarget trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26:3080-6.
21. Hermansen K, Davies M, Derezinski T, Martinez Ravn G, Clauson P, Home P. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006;29:1269-74.
22. Segel SA, Paramore DS, Cryer PE. Hypoglycemia-associated autonomic failure in advanced type 2 diabetes. Diabetes 2002;51:724-33.
23. Dagogo-Jack SE, Craft S, Cryer PE. Hypoglycemia-associated autonomic failure in insulin-dependent diabetes mellitus. Recent antecedent hypoglycemia reduces autonomic responses to, symptoms of, and defense against subsequent hypoglycemia. J Clin Invest 1993, 91:819-28.
24. Salzman R, Manson JE, Griffing GT, Kimmerle R, Ruderman N, McCall AL et al. Intranasal aerosolized insulin. Mixed-meal studies and long-term use in type I diabetes. N Engl J Med 1985;312:1078-84.
25. Royle P, Waugh N, Deakin M, Philip S. WITHDRAWN: Inhaled insulin in diabetes mellitus. Cochrane Database Syst Rev 2009;1:CD003890.
26. Wredling R, Liu D, Lins PE, Adamson U. Variation of insulin absorption during subcutaneous and peritoneal infusion in insulin dependent diabetic patients with unsatisfactory long-term glycaemic response to continuous subcutaneous insulin infusion. Diabetes Metab 1991;17:456-9.
27. Micossi P, Cristallo M, Librenti MC, Petrella G, Galimberti G, Melandri M et al. Free-insulin profiles after intraperitoneal intramuscular, subcutaneous insulin administration. Diabetes Care 1986;9:575-8.
28. Nathan DM, Dunn FL, Bruch J, McKitrick C, Larkin M, Haggan C et al. Postprandial insulin profiles with implantable pump therapy may explain decreased frequency of severe hypoglycaemia, compared with intensive subcutaneous regimens, in insulindependent diabetes mellitus patients. Am J Med 1996;100:412-7.
29. Giacca A, Caumo A, Galimberti G, Petrella G, Librenti MC, Scavini M et al. Peritoneal and subcutaneous absorption of insulin in type I diabetic subjects. J Clin Endocrinol Metab 1993;77:738-42.
30. Wan CK, Giacca A, Matsuhisa M, El-Bahrani B, Lam L, Rodgers C et al. Increased responses of glucagon and glucose production to hypoglycemia with intraperitoneal versus subcutaneous insulin treatment. Metabolism 2000;49:984-9.
31. Logtenberg SJ, Kleefstra N, Houweling ST, Groenier KH, Gans RO, van Ballegooie E et al.. Improved glycemic control with intraperitoneal versus subcutaneous insulin in type 1 diabetes: a randomized controlled trial. Diabetes Care 2009;32:1372-7.
32. Unger RH, Orci L. Paracrinology of islets and the paracrinopathy of diabetes. Proc Natl Acad Sci USA 2010;107:16009-12.
33. Lee Y, Wang MY, Du XQ, Charron MJ, Unger RH. Glucagon receptor knockout prevents insulin-deficient type 1 diabetes in mice. Diabetes 2011;60:391-7.
34. Wang MY, Chen L, Clark GO, Lee Y, Stevens RD, Ilkayeva OR et al. Leptin therapy in insulin-deficient type I diabetes. Proc Natl Acad Sci USA 2010;107:4813-9.
35. Cryer PE. Hypoglycemia is the limiting factor in the management of diabetes. Diabetes Metab Res Rev 1999;15:42-6.
36. Cryer PE. Hypoglycemia the limiting factor in the glycaemic management of type I and type II diabetes. Diabetologia 2002;45:937-48.
37. Ramnanan CJ, Edgerton DS, Kraft G, Cherrington AD. Physiologic action of glucagon on liver glucose metabolism. Diabetes Obes Metab 2011;13(Suppl 1):118-25.
38. Ruedy KJ, Tamborlane WV, Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. The landmark JDRF continuous glucose monitoring randomized trials: a look back at the accumulated evidence. J Cardiovasc Transl Res 2012;5:380-7.
39. McGarraugh G, Bergenstal R. Detection of hypoglycemia with continuous interstitial and traditional blood glucose monitoring using the FreeStyle Navigator Continuous Glucose Monitoring System. Diabetes Technol Ther 2009;11:145-50.
40. Miller KM, Beck RW, Bergenstal RM, Goland RS, Haller MJ, McGill JB et al. Evidence of a Strong Association Between Frequency of Self-Monitoring of Blood Glucose and Hemoglobin A1C Levels in T1D Exchange Clinic Registry Participants. Diabetes Care 2013 [Epub ahead of print].
41. Vazeou A. Continuous blood glucose monitoring in diabetes treatment. Diabetes Research and Clinical Practice 2011;93(Suppl 1):S125-30.
42. Beck RW, Tamborlane WV, Bergenstal RM, Miller KM, Dubose SN, Hall CA; T1D Exchange Clinic Network: The T1D Exchange Clinic Registry. J Clin Endocrinol Metab 2012;97:4383-9.
43. Bergenstal RM, Ahmann AJ, Bailey T, Beck RW, Bissen J, Buckingham B et al. Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: The Ambulatory Glucose Profile (AGP). Diabetes Technol Ther 2013;15:198-211.
44. Centers for Disease Control and Prevention: Mean/Median Ale Among Adults with Diagnosed Diabetes, United States, 1988-1994 to 1999-2006 [Internet]. Available at: http://www.cdc.gov/diabetes/statistics/alc/Alc-Mean-Median.htm [cited 2013, Apr. 16].
45. McCall AL, Kovatchev BP. The median is not the only message: a clinician's perspective on mathematical analysis of glycemic variability and modeling in diabetes mellitus. J Diabetes Sci Technol 2009;3:3-11.
46. Frier BM. How hypoglycaemia can affect the life of a person with diabetes. Diabetes Metab Res Rev 2007;24:87-92.
47. Clarke WL, Cox DJ, Gonder-Frederick L, Julian D, Kovatchev B, Young-Hyman D. Biopsychobehavioral model of risk of severe hypoglycemia. Self-management behaviors. Diabetes Care 1999;22:580-4.
48. Kovatchev BP, Cox DJ, Farhy LS, Straume M, Gonder-Frederick L, Clarke WL. Episodes of severe hypoglycemia in type 1 diabetes are preceded and followed within 48 hours by measurable disturbances in blood glucose. J Clin Endocrinol Metab 2000;85:4287-92.
49. Cox D, Gonder-Frederick L, McCall A, Kovatchev B, Clarke W. The effects of glucose fluctuation on cognitive function and QOL: the functional costs of hypoglycaemia and hyperglycaemia among adults with type 1 or type 2 diabetes. Int J Clin Pract Suppl 2002;129:20-6.
50. Clemens AH, Chang PH, Myers RW. The development of Biostator, a Glucose Controlled Insulin Infusion System (GCIIS) Horm Metab Res 1977;(Suppl 7):23-33.
51. Steil GM, Rebrin K, Darwin C, Hariri F, Saad MR Feasibility of automating insulin delivery for the treatment of type 1 diabetes. Diabetes 2006;55:3344-50.
52. Weinzimer SA, Steil GM, Swan KL, Dziura J, Kurtz N, Tamborlane WV. Fully automated closed-loop insulin delivery versus semiautomated hybrid control in pediatric patients with type 1 diabetes using an artificial pancreas. Diabetes Care 2008;31:934-9.
53. Parker RS, Doyle FJ, 3rd, Peppas NA. A model-based algorithm for blood glucose control in Type I diabetic patients. IEEE Trans Biomed Eng 1999;48:148-57.
54. Hovorka R, Canonico V, Chassin LJ, Haueter U, Massi-Benedetti M, Orsini Federici M et al. Nonlinear model predictive control of glucose concentration in subjects with type 1 diabetes. Physiol Meas 2004;25:905-20.
55. Dua P, Doyle FJ, 3rd, Pistikopoulos EN. Modelbased blood glucose control for type 1 diabetes via parametric programming. IEEE Trans Biomed Eng 2006;53:1478-91.
56. Magni L, Raimondo F, Bossi L, Dalla Man C, De Nicolao G, Kovatchev BP et al. Model predictive control of type 1 diabetes: an in silico trial. J Diabetes Sci Technol 2007;1:804-12.
57. Kovatchev B, Patek S, Dassau E, Doyle FJ, 3rd, Magni L, De Nicolao G et al. Juvenile Diabetes Research Foundation Artificial Pancreas Consortium. Control to range for diabetes: functionality and modular architecture. J Diabetes Sci Technol 2009;3:1058-65.
58. Renard EM, Farret A, Place J, Cobelli C, Kovatchev BP, Breton MD. Closed-loop insulin delivery using subcutaneous infusion and glucose sensing, and equipped with a dedicated safety supervision algorithm, improves safety of glucose control in type 1 diabetes. Proc 46th EASD Annual Mtg, Stockholm, 2010.
59. Buckingham B et al. Prevention of Nocturnal Hypoglycemia Using Predictive Alarm Algorithms and Insulin Pump Suspension. Diabetes Care published ahead of print March 3, 2010.
60. Breton M, Farret A, Bruttomesso D, Anderson S, Magni L, Patek S et al. Fully integrated artificial pancreas in type 1 diabetes: modular closed-loop glucose control maintains near normoglycemia. Diabetes 2012;61:2230-7.
61. Kovatchev BP, Breton MD, Dalla Man C, Cobelli C. In Silico Preclinical Trials: A Proof of Concept in Closed-Loop Control of Type 1 Diabetes. J Diabetes Sci Technol 2009;3:44-55.
62. Patek SD, Bequette BW, Breton MD, Buckingham BA, Dassau E, Doyle FJ 3rd et al. In silico preclinical trials: methodology and engineering guide to closedloop control in type 1 diabetes mellitus. J Diabetes Sci Technol 2009;3:269-82.
63. Bergman RN, Ider YZ, Boeden CR, Cobelli C. Quantitative estimation of insulin sensitivity. Am J Physiol 1979;236:E667-77.
64. Dalla Man C, Caumo A, Basu R, Rizza R, Toffolo G, Cobelli C. Minimal model estimation of glucose absorption and insulin sensitivity from oral test: validation with a tracer method. Am J Physiol Endocrinol Metab 2004;287:E637-43.
65. Breton MD, Kovatchev BP. Impact of blood glucose self-monitoring errors on glucose variability, risk for hypoglycemia, and average glucose control in type 1 diabetes: an in silico study. J Diabetes Sci Technol 2010;4:562-70.
66. Breton MD, Clarke WL, Farhy LS, Kovatchev BP. A model of self-treatment behavior, glucose variability, and hypoglycemia-associated autonomic failure in type 1 diabetes. J Diabetes Sci Technol 2007;1:331-7.
67. Harvey RA, Wang Y, Grosman B, Percival MW, Bevier W, Finan DA et al. Quest for the artificial pancreas: combining technology with treatment. IEEE Eng Med Biol Mag 2010;29:53-62.
68. Klonoff D. The need for a glycemia modeling comparison workshop to facilitate development of an artificial pancreas. J Diabetes Sci Technol 2010;4:1-3.
69. Farhy LS, McCall AL. Optimizing reduction in basal hyperglucagonaemia to repair defective glucagon counterregulation in insulin deficiency Diabetes Obes Metab 2011;13(Suppl. 1):133-43.
70. Farhy LS, McCall AL. Models of Glucagon Secretion, Their Application to the Analysis of the Defects in Glucagon Counterregulation and Potential Extension to Approximate Glucagon Action. J Diabetes Sci Technol 2010;4:1345-56.
71. Farhy LS, McCall AL. System-Level Control to Optimize Glucagon Counterregulation by Switch-Off of α-Cell Suppressing Signals in β-Cell Deficiency. J Diabetes Sci Technol 2009;3:21-33
72. Farhy LS, Chan A, Breton MD, Anderson SM, Kovatchev BP, McCall AL. Association of Basal Hyperglucagonemia with Impaired Glucagon Counterregulation in Type 1 Diabetes. Front Physiol 2012;3:40.
73. Farhy LS, Du Z, Zeng Q, Veldhuis PP, Johnson ML, Brayman KL et al. Amplification of pulsatile glucagon counterregulation by switch-off of a-cell-suppressing signals in streptozotocin-treated rats. Am J Physiol Endocrinol Metab 2008;295:E575-85.